Company: CeMM Research Centre for Molecular Medicine
Job title: Principal Investigator
Dr. Winter conducted his postdoctoral studies at the Dana Farber Cancer Institute under the supervision of Jay Bradner. During this time, he developed the first generalizable solution for in vivo protein degradation based on heterobifunctional degraders hijacking the CRBN E3 ligase. Since 2016, he is leading his independent research group, intersecting high-throughput technologies (functional genomics, transcriptomics, proteomics, phenotypic chemical screening) with targeted protein degradation to develop next generation degraders, and to dissect and disrupt gene control mechanisms in health and disease. Georg Winter’s work is recognized by multiple awards such as the Eppendorf Award, and supported by multiple national and international grants, including an ERC Starting grant awarded in 2019.
Discussion/Q&A 10:00 am
day: Day One
Discovery of Molecular Glue Degraders via Phenotypic Chemical Screens 9:40 am
Coupling genome-scale CRISPR screens with degrader treatment identifies a comprehensive network of cellular effectors required for efficient TPD Development of isogenic, hyponeddylated cell line models based on this effector network empowered differential chemical screening to identify novel and molecular glue degraders Multi-omics target identification led us to identify novel degraders of Cyclin K that operate…Read more
day: Day One